Cybin Corp., a Canada-based life-science company, looks to benefit from its growing footprint in two billion-dollar markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see significant growth in the coming years. The global nutraceutical market was valued at $382.51 billion in 2019 and is expected to grow at an 8.3% compound annual growth … Continue reading “NetworkNewsBreaks – Cybin Corp. Leverages Two-Pronged Approach to Target Psychedelic, Nutraceutical Sectors”
Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model Cybin Corp. to capitalize on international expansion of psilocybin use as a company active in both research, nonclinical spaces … Continue reading “United Bid to Liberalize Use of Psilocybin Strengthens”
Cybin announces appointment of established pharma industry figure as new CEO Drysdale leverages 30 years of leadership, entrepreneurial experience in life-science space Announcement comes as Cybin sets out on path to profitability Cybin Corp., an innovative life science company developing mushroom-derived psychedelic pharmaceuticals and nonpsychedelic nutraceutical products, has announced the appointment of Mr. Doug Drysdale … Continue reading “Cybin Corp. New CEO Set to Pave Path to Profitability, Grow IP Portfolio Organically”
Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market Cybin Corp., a Canadian early-stage life sciences company appears … Continue reading “Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets”
Cybin, a life-sciences company focused on advancing psychedelic and nutraceutical-based products, today announced that its CEO, Doug Drysdale, is featured in an exclusive audio interview with NetworkNewsWire (“NNW”) – a financial news and content distribution company and one of 50+ brands in the InvestorBrandNetwork (“IBN”). During the interview, Drysdale provides insight into Cybin’s 2020 milestones, … Continue reading “NetworkNewsBreaks – Cybin Corp. CEO Discusses Milestones, Goals and Momentum in Exciting Emerging Industry”
Cybin Corp. is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit the company’s website at … Continue reading “NetworkNewsAudio – Cybin Corp. Interview”
Cybin Corp., an exemplary Canada-based, life-science company focused on the development of pharmaceutical-grade psilocybin products, is at the forefront of change in an era open to exploring psychedelic treatment options where big pharma has failed. Started in the 1940s, but kiboshed in the 1960s with President Richard Nixon’s war on drugs, researchers have once again … Continue reading “NetworkNewsBreaks – Cybin Corp. Focused on Advancing New Products Amid Positive Research in Psychedelics”
Revive Therapeutics (CSE: RVV) OTC: RVVTF), a specialty life-sciences company focused on the research and development of therapeutics for medical needs and rare disorders, has finalized a clinical trial agreement with the Board of Regents of the University of Wisconsin System (“UWS”). The agreement calls for Revive Therapeutics to conduct a clinical study entitled “Phase … Continue reading “NetworkNewsBreaks – Revive Therapeutics Ltd. (CSE: RVV) (OTC: RVVTF) to Evaluate Psilocybin in Methamphetamine Use Disorder Treatment Clinical Trial”
Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated … Continue reading “NetworkNewsBreaks — Cybin Corp. Names Health-Care, M&A Expert as New Chief Executive Officer”
Company focused on furthering R&D of psilocybin-based medications Cybin believes psychedelic substances derived from mushrooms can work as boosters for brain Psilocybin shows promise for an array of mental health issues Cybin Corp. is a leading life-science company focused on psychedelic and nutraceutical products to support various psychiatric and neurological conditions. The company is engaged … Continue reading “Cybin Corp. at Forefront of Change in Psilocybin-Based Treatments”
